Muna Therapeutics
Cillian King is an Investment Manager at LSP, one of Europe’s leading Life Sciences investors, and is fully dedicated to the LSP Dementia Fund.
Prior to joining LSP, Cillian was an Investment Manager at Swanbridge Capital, a venture fund focused on early-stage life sciences companies. At Swanbridge, Cillian led seed investments into biotech companies and served on the Boards of Allero Therapeutics and Pan Cancer T. Cillian is a molecular biologist by training and holds a PhD in Molecular Neurosciences.
This person is not in the org chart
This person is not in any offices
Muna Therapeutics
1 followers
Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.